AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$ANIX

Titterton Lewis H jr purchased $27K of ANIX

Titterton Lewis H jr purchased 10,000 shares of Anixa Biosciences Inc (ANIX) at $2.73 on 2026-09-10.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Sep 14, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIX
Neutral
medium confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXNeutralLow
01

Why it matters

The transaction is too small to affect market perception materially.

02

Market read

Limited relevance; likely no immediate trading action.

03

What to watch

Potential upcoming clinical data or partnership not disclosed.

Relevance 4/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; this is a routine purchase by a director.

Company-level read

Ticker impact

$ANIXNeutralMedium confidence
Context

Director Titterton Lewis H Jr purchased 10,000 shares of Anixa Biosciences for $27,300, disclosed via Form 4.

Expected impact

little to no immediate price effect

Evidence & confidence

Purchase amount is small relative to total holdings and market cap; unlikely to move price.

Market effects

Sector

None significant for biotech sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider purchase could be a subtle bullish signal despite small size.

Key entities

  • Company
    Anixa Biosciences Inc

    Biotech firm listed on NASDAQ under ticker ANIX.

  • Person
    Titterton Lewis H Jr

    Director of Anixa Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIX insider trading history →

Related articles

OCT 6
$ANIXMedAI 8/10

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

investing.com2 min
OCT 5
$ANIXMed

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences reported that a patient in its Phase 1 trial for ovarian cancer CAR-T therapy showed stable disease 3 months post-treatment. No dose-limiting toxicities were observed. The trial, conducted at Moffitt Cancer Center, aims to assess safety and preliminary efficacy of lira-cel, a novel CAR-T therapy targeting FSHR. Multiple patients have survived over a year, with one exceeding two years.

prnewswire.com2 min
OCT 1
$ANIXMedAI 8/10

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.

prnewswire.com2 min
SEP 11
$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

finanznachrichten.de2 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min